The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B
Abstract
We studied the long-term efficacy of adefovir dipivoxil (ADV) treatment in 42 HBeAg-negative patients with chronic hepatitis B (CHB) who had developed genotypical lamivudine (LAM) resistance with virological and clinical breakthroughs under long-term LAM treatment. Patients were allocated in 2 treatment groups. In the first (n = 14), LAM was switched to ADV monotherapy whereas in the second (n = 28) ADV was added to LAM. The two groups did not differ in patients' characteristics, all of them having HBV genotype D infection with the precore stop codon mutation. Within 12 months from start of ADV treatment, serum HBV DNA became nondetectable and ALT normalized in 71% and 90% of patients, respectively, with no difference between the 2 arms. Patients with baseline HBV DNA levels less than 107 copies/ml experienced a significantly earlier and more frequent decline in serum HBV DNA to nondetectable levels as compared with patients with greater than 107 HBV DNA copies/ml at baseline ( P = 0.0013) This response has hitherto been maintained (median treatment duration 40 months) in all patients with ADV added to LAM, whereas virological and biochemical breakthroughs due to development of ADV signature resistance mutations occurred in 3 of 14 patients (21%) on ADV monotherapy 15 to 18 months from start of treatment ( P = 0.0174). Conclusion: Adding ADV to LAM in HBeAg-negative CHB patients with LAM resistance effectively suppresses HBV replication in most of them and induces biochemical remission that can be maintained in all of them at least for 3 years without any evidence of development of resistance to ADV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B
Marcellin, P., Chang, T.-T., Lim, S. G., Tong, M. J., Sievert, W., Shiffman, M. L., Jeffers, L., Goodman, Z., Wulfsohn, M. S., Xiong, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020681 · Cited by 1,336
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B
Hadziyannis, S. J., Tassopoulos, N. C., Heathcote, E. J., Chang, T.-T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S. G., Goodman, Z., Wulfsohn, M. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021812 · Cited by 995
Self-citationAngus, P., Vaughan, R., Xiong, S., Yang, H., Delaney, W., Gibbs, C., Brosgart, C., Colledge, D., Edwards, R., Ayres, A., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00939-9 · Cited by 564
Hepatitis B e antigen-negative chronic hepatitis B
Hadziyannis, S. J., & Vassilopoulos, D. (2001) · Hepatology · doi:10.1053/jhep.2001.27834 · Cited by 554
Self-citationPeters, M. G., Hann, H. W., Martin, P., Heathcote, E. J., Buggisch, P., Rubin, R., Bourliere, M., Kowdley, K., Trepo, C., Gray, D. F., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.10.051 · Cited by 552
Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B
Hadziyannis, S. J., Tassopoulos, N. C., Heathcote, E. J., Chang, T.-T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S. G., Goodman, Z., Ma, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042957 · Cited by 531
Self-citationChronic hepatitis B: Update of recommendations† ‡
Lok, A. S. F., & McMahon, B. J. (2004) · Hepatology · doi:10.1002/hep.20110 · Cited by 500
Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B
Sherman, M., Yurdaydin, C., Sollano, J., Silva, M., Liaw, Y., Cianciara, J., Boron–Kaczmarska, A., Martin, P., Goodman, Z., Colonno, R., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.04.007 · Cited by 413
van Bömmel, F., Wünsche, T., Mauss, S., Reinke, P., Bergk, A., Schürmann, D., Wiedenmann, B., & Berg, T. (2004) · Hepatology · doi:10.1002/hep.20464 · Cited by 389
Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection
Chu, C.-J., Hussain, M., & Lok, A. S. F. (2002) · Hepatology · doi:10.1002/hep.1840360617 · Cited by 295
Cited by
Dienstag, J. L. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801644 · Cited by 961
Lampertico, P., Viganò, M., Manenti, E., Iavarone, M., Sablon, E., & Colombo, M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.08.079 · Cited by 310
Metadata
- Authors
- Rapti, I., Dimou, E., Mitsoula, P., & Hadziyannis, S. J.
- Venue
- Hepatology
- Published
- 2007-02
- Volume
- 45
- Issue
- 2
- Pages
- 307-313
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2142557452
- Cited by
- 323
- References
- 15
- FWCI
- 34.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. https://app.cochat.ai/papers/10.1002/hep.21534
- The paper
- Rapti, I., Dimou, E., Mitsoula, P., & Hadziyannis, S. J. (2007). Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology. https://doi.org/10.1002/hep.21534
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
